Ecaterina Iavrumov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ecaterina Iavrumov has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alexandru Corlateanu
Department of Respiratory Medicine, State University of Medicine and Pharmacy “Nicolae Testemitanu”, Chisinau, Moldova
4 shared publications - Alexandr Ceasovschih
Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania
2 shared publications - Dumitru Cravcenco
Medical Center Scanexpert, 2001 Chisinau, Moldova
2 shared publications - Nikolaos Siafakas
Clinical Microbiology Laboratory, “Attikon” University General Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece
2 shared publications - Pradeesh Sivapalan
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen
2 shared publications Alexandru Corlateanu
State University of Medicine and Pharmacy “Nicolae Testemitanu”, Department of Respiratory Medicine and allergology, Chisinau, Republic of Moldova
1 shared publication
Latest Publications
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , OA1272
Multimorbidity patterns in chronic obstructive pulmonary disease and their associations with disease severity
Background: Chronic obstructive pulmonary disease (COPD) is increasingly recognized as a systemic condition frequently accompanied by multiple comorbidities. While comorbidity burden has been extensively studied, less is known about distinct multimorbidity patterns and their relationship with disease severity. Identifying such patterns may improve clinical phenotyping and risk stratification. Methods. Cross-sectional study of 180 spirometry-confirmed COPD patients. Comorbidities were recorded and hierarchical cluster analysis identified multimorbidity patterns. Severity was assessed by FEV₁ (% predicted), GOLD 2026 ABE, CAT, mMRC, exacerbations and hospitalizations in the previous year, and all-cause mortality. Logistic regression evaluated independent associations with severe COPD and mortality. Results. Three clusters were identified: cardiovascular–metabolic (41%), psychiatric–symptomatic (31%), and musculoskeletal–frailty (28%). The cardiovascular–metabolic cluster had higher GOLD E prevalence (70% vs 48% and 52%; p=0.011), lower FEV₁ (40% vs 48% and 46%; p=0.019), more hospitalizations (1.6 vs 0.8 and 0.9; p=0.004), and higher mortality (8% vs 3,5% and 4%; p=0.038). It independently predicted severe COPD (OR 2.89; p=0.003) and mortality (OR 2.42; p=0.031). Conclusions. Distinct multimorbidity clusters are present in COPD and are differentially associated with disease severity, hospitalization burden and mortality. Cluster-based phenotyping may refine GOLD classification and improve risk stratification beyond spirometric assessment alone.
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , OA1272
Multimorbidity patterns in chronic obstructive pulmonary disease and their associations with disease severity
Background: Chronic obstructive pulmonary disease (COPD) is increasingly recognized as a systemic condition frequently accompanied by multiple comorbidities. While comorbidity burden has been extensively studied, less is known about distinct multimorbidity patterns and their relationship with disease severity. Identifying such patterns may improve clinical phenotyping and risk stratification. Methods. Cross-sectional study of 180 spirometry-confirmed COPD patients. Comorbidities were recorded and hierarchical cluster analysis identified multimorbidity patterns. Severity was assessed by FEV₁ (% predicted), GOLD 2026 ABE, CAT, mMRC, exacerbations and hospitalizations in the previous year, and all-cause mortality. Logistic regression evaluated independent associations with severe COPD and mortality. Results. Three clusters were identified: cardiovascular–metabolic (41%), psychiatric–symptomatic (31%), and musculoskeletal–frailty (28%). The cardiovascular–metabolic cluster had higher GOLD E prevalence (70% vs 48% and 52%; p=0.011), lower FEV₁ (40% vs 48% and 46%; p=0.019), more hospitalizations (1.6 vs 0.8 and 0.9; p=0.004), and higher mortality (8% vs 3,5% and 4%; p=0.038). It independently predicted severe COPD (OR 2.89; p=0.003) and mortality (OR 2.42; p=0.031). Conclusions. Distinct multimorbidity clusters are present in COPD and are differentially associated with disease severity, hospitalization burden and mortality. Cluster-based phenotyping may refine GOLD classification and improve risk stratification beyond spirometric assessment alone.
- Open Access
- 19 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 785
Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease Patients by Chest High Resolution Computed Tomography (HRCT)
Purpose: Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory condition often accompanied by various comorbidities that significantly affect patient outcomes. High resolution computed tomography (HRCT) has emerged as a valuable tool for diagnosing and managing COPD-related comorbidities. This study aimed to explore the impact of chest computed tomography (CT) imaging in identifying and characterizing comorbidities in COPD patients. Methods: The study was conducted on 99 patients with COPD, the median age of the study population was 70.0 years (Q1–Q3: 62.0–75.0); 86% were men (85), and 14% were women (14). All patients underwent chest HRCT to identify the presence of comorbidities. Results: According to the GOLD classification (ABE groups), 3% were type A, 27% were type B, and 69% were type E. The prevalence of comorbidities identified on chest HRCT was reported as 66% for coronary artery calcification (CAC), 83% for osteoporosis, 36% for pulmonary artery enlargement (PAE), 31% for emphysema, 19% for bronchiectasis, 17% for hiatal hernia, 14% for lung cancer, 12% pulmonary infections, and 3% for interstitial abnormalities. In 4%, there were no comorbidities, one comorbidity was found in 11%, two comorbidities in 17%, and three comorbidities and more in 68% of cases. Conclusions: Chest HRCT imaging serves as a valuable tool for identifying and assessing comorbidities in patients with COPD. Incorporating chest CT imaging into the routine evaluation of COPD patients may contribute to a more comprehensive understanding of their condition and lead to better clinical outcomes.
- 19 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 785
Open AccessAssessment of Comorbidities in Chronic Obstructive Pulmonary Disease Patients by Chest High Resolution Computed Tomography (HRCT)
Purpose: Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory condition often accompanied by various comorbidities that significantly affect patient outcomes. High resolution computed tomography (HRCT) has emerged as a valuable tool for diagnosing and managing COPD-related comorbidities. This study aimed to explore the impact of chest computed tomography (CT) imaging in identifying and characterizing comorbidities in COPD patients. Methods: The study was conducted on 99 patients with COPD, the median age of the study population was 70.0 years (Q1–Q3: 62.0–75.0); 86% were men (85), and 14% were women (14). All patients underwent chest HRCT to identify the presence of comorbidities. Results: According to the GOLD classification (ABE groups), 3% were type A, 27% were type B, and 69% were type E. The prevalence of comorbidities identified on chest HRCT was reported as 66% for coronary artery calcification (CAC), 83% for osteoporosis, 36% for pulmonary artery enlargement (PAE), 31% for emphysema, 19% for bronchiectasis, 17% for hiatal hernia, 14% for lung cancer, 12% pulmonary infections, and 3% for interstitial abnormalities. In 4%, there were no comorbidities, one comorbidity was found in 11%, two comorbidities in 17%, and three comorbidities and more in 68% of cases. Conclusions: Chest HRCT imaging serves as a valuable tool for identifying and assessing comorbidities in patients with COPD. Incorporating chest CT imaging into the routine evaluation of COPD patients may contribute to a more comprehensive understanding of their condition and lead to better clinical outcomes.
- Open Access
- 4 January 2026
- Published by MDPI AG in Preprints.org
Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease Patients by Chest High Resolution Computed Tomography (HRCT)
Purpose: Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory condition often accompanied by various comorbidities that significantly affect patient outcomes. High resolution computed tomography has emerged as a valuable tool for diagnosing and managing COPD-related comorbidities. This study aims to explore the impact of chest CT imaging in identifying and characterizing comorbidities in COPD patients. Methods: The study was conducted on 99 patients with COPD, with an average age of 67,8 (37-88), 86% were men (85), and 14% were women (14). The patients underwent chest HRCT to identify the presence of comorbidities. Results: According to the GOLD classification, ABE type, 3% were type A, 27% were type B, and 69% were type E. The prevalence of comorbidities identified on chest HRCT was reported as 66% for coronary artery calcification (CAC), 83% for osteoporosis, 36% for pulmonary artery enlargement (PAE), 31% for emphysema, 19% for bronchiectasis, 17% for hiatal hernia, 14% for lung cancer, 12% pulmonary infections and 3% for interstitial abnormalities. In 4% there were no comorbidities, one comorbidity was found in 11%, two comorbidities in 17%, and three comorbidities and more in 68% of cases. Conclusion: Chest HRCT imaging serves as a valuable tool for identifying and assessing comorbidities in patients with COPD. Incorporating chest CT imaging into the routine evaluation of COPD patients can contribute to a more comprehensive understanding of their condition and lead to better clinical outcomes.
- 4 January 2026
- Published by MDPI AG in Preprints.org
Open AccessAssessment of Comorbidities in Chronic Obstructive Pulmonary Disease Patients by Chest High Resolution Computed Tomography (HRCT)
Purpose: Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory condition often accompanied by various comorbidities that significantly affect patient outcomes. High resolution computed tomography has emerged as a valuable tool for diagnosing and managing COPD-related comorbidities. This study aims to explore the impact of chest CT imaging in identifying and characterizing comorbidities in COPD patients. Methods: The study was conducted on 99 patients with COPD, with an average age of 67,8 (37-88), 86% were men (85), and 14% were women (14). The patients underwent chest HRCT to identify the presence of comorbidities. Results: According to the GOLD classification, ABE type, 3% were type A, 27% were type B, and 69% were type E. The prevalence of comorbidities identified on chest HRCT was reported as 66% for coronary artery calcification (CAC), 83% for osteoporosis, 36% for pulmonary artery enlargement (PAE), 31% for emphysema, 19% for bronchiectasis, 17% for hiatal hernia, 14% for lung cancer, 12% pulmonary infections and 3% for interstitial abnormalities. In 4% there were no comorbidities, one comorbidity was found in 11%, two comorbidities in 17%, and three comorbidities and more in 68% of cases. Conclusion: Chest HRCT imaging serves as a valuable tool for identifying and assessing comorbidities in patients with COPD. Incorporating chest CT imaging into the routine evaluation of COPD patients can contribute to a more comprehensive understanding of their condition and lead to better clinical outcomes.
- 1 September 2025
- Published by Periodic Publication Moldovan Journal of Health Sciences in Moldovan Journal of Health Sciences
- Vol. 12 (3) , 60-65
The impact of comorbidities on chronic obstructive pulmonary disease
Introduction. Chronic obstructive pulmonary disease is a major cause of morbidity and mortality worldwide, often associated with multiple comorbidities that may complicate its clinical course. These comorbidities can exacerbate respiratory symptoms, impair lung function, alter imaging findings, and significantly affect prognosis. Material and methods. This analytical, observational, cross-sectional study included 80 patients with confirmed chronic obstructive pulmonary disease, divided into two equal subgroups according to spirometric severity: GOLD 1-2 (n = 40) and GOLD 3-4 (n = 40). Clinical, functional, and radiological parameters were evaluated. Comorbidity burden was assessed using validated composite indices: Charlson Comorbidity Index, COTE, COPDCoRi, CODEX, and COMCOLD. Associations between comorbidity scores, pulmonary function, high-resolution computed tomography findings, and clinical outcomes were analyzed using SPSS v22.0. A p-value less than 0.05 was considered statistically significant. Results. The presence of comorbidities was high across all domains, with only minor differences between spirometric stages. Structural abnormalities (emphysema, bronchiectasis, pulmonary hypertension) were more prevalent in GOLD 3-4 patients. A strong correlation was observed between composite indices and parameters such as forced expiratory volume in 1 second, dyspnea, exacerbation rate, radiological findings, and GOLD stages. Logistic regression models showed that the combination of COPD-specific indices (COTE, CODEX, COPDCoRi) significantly outperformed the Charlson index in predicting severe COPD (AUC 0.86 vs. 0.63). High-resolution computed tomography findings variables also demonstrated strong predictive value (AUC 0.81). Conclusions. Comorbidities play a central role in shaping chronic obstructive pulmonary disease severity and prognosis. The integration of composite comorbidity indices and imaging biomarkers enhances multidimensional patient stratification, aligning with GOLD 2024 recommendations for personalized care
- 1 September 2025
- Published by Periodic Publication Moldovan Journal of Health Sciences in Moldovan Journal of Health Sciences
- Vol. 12 (3) , 60-65
The impact of comorbidities on chronic obstructive pulmonary disease
Introduction. Chronic obstructive pulmonary disease is a major cause of morbidity and mortality worldwide, often associated with multiple comorbidities that may complicate its clinical course. These comorbidities can exacerbate respiratory symptoms, impair lung function, alter imaging findings, and significantly affect prognosis. Material and methods. This analytical, observational, cross-sectional study included 80 patients with confirmed chronic obstructive pulmonary disease, divided into two equal subgroups according to spirometric severity: GOLD 1-2 (n = 40) and GOLD 3-4 (n = 40). Clinical, functional, and radiological parameters were evaluated. Comorbidity burden was assessed using validated composite indices: Charlson Comorbidity Index, COTE, COPDCoRi, CODEX, and COMCOLD. Associations between comorbidity scores, pulmonary function, high-resolution computed tomography findings, and clinical outcomes were analyzed using SPSS v22.0. A p-value less than 0.05 was considered statistically significant. Results. The presence of comorbidities was high across all domains, with only minor differences between spirometric stages. Structural abnormalities (emphysema, bronchiectasis, pulmonary hypertension) were more prevalent in GOLD 3-4 patients. A strong correlation was observed between composite indices and parameters such as forced expiratory volume in 1 second, dyspnea, exacerbation rate, radiological findings, and GOLD stages. Logistic regression models showed that the combination of COPD-specific indices (COTE, CODEX, COPDCoRi) significantly outperformed the Charlson index in predicting severe COPD (AUC 0.86 vs. 0.63). High-resolution computed tomography findings variables also demonstrated strong predictive value (AUC 0.81). Conclusions. Comorbidities play a central role in shaping chronic obstructive pulmonary disease severity and prognosis. The integration of composite comorbidity indices and imaging biomarkers enhances multidimensional patient stratification, aligning with GOLD 2024 recommendations for personalized care
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA3886
Assessment of comorbidities in COPD patients by chest HRCT
Background and objective: COPD is a progressive respiratory condition often accompanied by various comorbidities that significantly affect patient outcomes. HRCT imaging has emerged as a valuable tool for diagnosing and managing COPD-related comorbidities. This study aims to explore the impact of chest CT imaging in identifying and characterizing comorbidities in COPD patients. Methods: The study was conducted on 99 patients with COPD, with an average age of 67,8 (37-88), 85% were men (85), and 14% were women (14). The patients underwent chest computed tomography to identify the presence of imaging comorbidities. Results: According to the GOLD classification, ABE type, 3% were type A, 27% were type B, and 69% were type E. The prevalence of comorbidities identified on chest HRCT was reported as 66% for coronary artery calcification, 83% for osteoporosis, 36% for pulmonary artery enlargement, 31% for emphysema, 19% for bronchiectasis, 17% for hiatal hernia, 14% for lung cancer, 12% pulmonary infections and 3% for interstitial abnormalities. In 4% there were no comorbidities, one comorbidity was found in 11%, two comorbidities in 17%, and three comorbidities and more in 68% of cases. Conclusion: Chest CT imaging serves as a valuable tool for identifying and assessing comorbidities in patients with COPD. Incorporating chest CT imaging into the routine evaluation of COPD patients can contribute to a more comprehensive understanding of their condition and lead to better clinical outcomes. KEYWORDS COPD, comorbidities, chest HRCT, chest computed tomography
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA3886
Assessment of comorbidities in COPD patients by chest HRCT
Background and objective: COPD is a progressive respiratory condition often accompanied by various comorbidities that significantly affect patient outcomes. HRCT imaging has emerged as a valuable tool for diagnosing and managing COPD-related comorbidities. This study aims to explore the impact of chest CT imaging in identifying and characterizing comorbidities in COPD patients. Methods: The study was conducted on 99 patients with COPD, with an average age of 67,8 (37-88), 85% were men (85), and 14% were women (14). The patients underwent chest computed tomography to identify the presence of imaging comorbidities. Results: According to the GOLD classification, ABE type, 3% were type A, 27% were type B, and 69% were type E. The prevalence of comorbidities identified on chest HRCT was reported as 66% for coronary artery calcification, 83% for osteoporosis, 36% for pulmonary artery enlargement, 31% for emphysema, 19% for bronchiectasis, 17% for hiatal hernia, 14% for lung cancer, 12% pulmonary infections and 3% for interstitial abnormalities. In 4% there were no comorbidities, one comorbidity was found in 11%, two comorbidities in 17%, and three comorbidities and more in 68% of cases. Conclusion: Chest CT imaging serves as a valuable tool for identifying and assessing comorbidities in patients with COPD. Incorporating chest CT imaging into the routine evaluation of COPD patients can contribute to a more comprehensive understanding of their condition and lead to better clinical outcomes. KEYWORDS COPD, comorbidities, chest HRCT, chest computed tomography